Secondary ALK-Positive Anaplastic Large Cell Lymphoma Masquerading as Inflammatory Breast Cancer
Abstract
Background: Secondary breast lymphoma accounts for 0.12% of breast malignancies. Anaplastic large cell lymphoma (ALCL) metastases to the breast are rare considering lymphoid tissue is a minor component of the breast. We describe a case of secondary ALK-positive ALCL identified during workup of inflammatory breast cancer in the setting of diffuse erythema, induration, and pitting lymphedema of the right breast with weeping serous fluid in a septic patient.
Case Presentation: A 28-year-old female presented with septic shock and two weeks of right breast pain, erythema, swelling, and fever. Imaging demonstrated a mass in the right axillary/sub-pectoral region and bilateral axillary, mediastinal, supraclavicular, and retroperitoneal lymphadenopathy. Physical exam demonstrated tenderness, diffuse erythema, induration, pitting lymphedema of the right breast with palpable lymphadenopathy concerning for inflammatory breast cancer. Punch biopsy was performed. Immunohistochemical analysis revealed CD30 and CD45 positivity. Fluorescent in-situ hybridization (FISH) reflex revealed ALK (2p23). Subsequent nodal biopsies revealed hallmark cells. The cumulative findings were indicative of ALK-positive ALCL.
Conclusions: This presentation underscores the importance of including lymphoma within the differential during workup of suspected inflammatory breast cancer.
Full text article
References
Picasso R, Tagliafico A, Calabrese M, Martinoli C, Pistoia F, Rossi A, et al. Primary and Secondary Breast Lymphoma: Focus on Epidemiology and Imaging Features. Pathol Oncol Res. 2020;26(3):1483–8. doi: 10.1007/s12253-019-00730-0
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 May 19;127(20):2375–90. doi: 10.1182/blood-2016-01-643569
Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood. 2000;96(13):4319–27. doi: 10.1182/blood.v96.13.4319
Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496–504. doi: 10.1182/blood-2008-01-134270
Sibon D, Fournier M, Brière J, Lamant L, Haioun C, Coiffier B, et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d’Étude des Lymphomes de l’Adulte Trials. J Clin Oncol. 2012;30(32):3939–46. doi: 10.1200/JCO.2012.42.2345
Delair DF, Corben AD, Catalano JP, Vallejo CE, Brogi E, Tan LK. Non-mammary metastases to the breast and axilla: A study of 85 cases. Mod Pathol. 2013;26(3):343–9. doi: 10.1038/modpathol.2012.191
Shim E, Song SE, Seo BK, Kim YS, Son GS. Lymphoma affecting the breast: A pictorial review of multimodal imaging findings. J Breast Cancer. 2013;16(3):254–65. doi: 10.4048/jbc.2013.16.3.254
Gualco G, Chioato L, Harrington WJ, Weiss LM, Bacchi CE. Primary and secondary T-cell lymphomas of the breast: clinico-pathologic features of 11 cases. Appl Immunohistochem Mol Morphol AIMM. 2009 Jul;17(4):301–6. doi: 10.1097/PAI.0b013e318195286d
Taron J, Fleischer S, Bahrs S, Preibsch H, Hattermann V, Hahn M, et al. Secondary Breast Lymphoma: A Case Report. Arch Hematol Case Rep Rev. 2017;2:19–21. doi: 10.1016/j.radcr.2023.12.018
Krishnan C, Moline S, Anders K, Warnke RA. Intravascular ALK -Positive Anaplastic Large-Cell Lymphoma Mimicking Inflammatory Breast Carcinoma. J Clin Oncol. 2009 May 20;27(15):2563–5. doi: 10.1200/JCO.2008.20.3984
Authors
Copyright (c) 2025 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.